Stimulate innovation in clinical evaluations and personalized medicine to improve product development and patient outcome.
Ended Definitive Contract Awarded Last action
- Contract number
- 75F40122C00161
- Awardee
-
Safe Health Systems, Inc. UEI CN6HSUM8VA77
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $9,671,431
Award facts
- Contract value 100% obligated
- $9,671,431.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 165 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $5,876,431 | |
| Original award | $3,795,000 |
About this award
Safe Health Systems, Inc. (UEI: CN6HSUM8VA77) has been awarded a $9.7 million firm fixed-price definitive contract by the Food and Drug Administration (FDA) to stimulate innovation in clinical evaluations and personalized medicine with the goal of improving product development and patient outcomes. The contract, awarded on September 27, 2022, carries an ultimate completion date of September 17, 2025, and will be performed in Silver Spring, Maryland. No set-aside designation was applied to this award.
This engagement supports the FDA's broader mission to advance regulatory science and modernize product evaluation methodologies. By focusing on clinical evaluation frameworks and personalized medicine approaches, the contract aims to enhance the agency's capacity to evaluate medical products more effectively while considering individual patient characteristics and treatment responses. The work directly contributes to the FDA's strategic objectives of strengthening product development pathways and ultimately improving patient health outcomes through more innovative and tailored therapeutic approaches.
Quick answers
Who was awarded contract 75F40122C00161?
75F40122C00161 was awarded to Safe Health Systems, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 27, 2022.
How much is contract 75F40122C00161 worth?
The government has obligated $9,671,431 on 75F40122C00161.
Was contract 75F40122C00161 competed?
The extent of competition for 75F40122C00161 was full and open competition. The government received 165 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award